China closing in but US leads in biotech quality and commercial reach, survey finds

A recent survey of senior US leaders in industry and academia, conducted by the Cure Innovation Index, indicates that while China leads in clinical drug trials and supply chain management within biomedical science, the United States maintains an advantage in quality and commercial reach. China is recognized as the leader in clinical development and supply chain sectors. Conversely, the US excels in transitioning experimental products to large-scale production, capital investment, commercialization, and talent. Both countries are considered tied in the area of scientific discovery. This survey highlights China's growing capabilities while underscoring the US's strengths in bringing innovations to market.